IWM, NVDQ: Big ETF Inflows
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 29 2024
0mins
Should l Buy INSM?
Source: NASDAQ.COM
ETF Inflows: The NVDQ ETF experienced the largest increase in inflows, adding 2,890,000 units, which represents a 36.6% rise in outstanding units.
Author's Opinion Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 143.980
Low
162.00
Averages
219.50
High
263.00
Current: 143.980
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insmed's Arikayce Trial Results Show Promise
- Buy Rating and Price Target: Truist has assigned a ‘Buy’ rating to Insmed shares with a price target of $205, indicating a potential upside of approximately 51% from Friday's closing price, reflecting strong market confidence in Insmed's future growth.
- Positive Trial Results: Insmed announced positive results from its trial of Arikayce for treating new occurrences of MAC lung infection, successfully meeting primary endpoints and demonstrating significant improvements in respiratory symptom scores and culture conversion rates, which may facilitate full FDA approval.
- Sales Growth Expectations: Truist analysts noted that while a better understanding of label expansion impacts is needed, they expect Arikayce's sales growth rate to remain stable, with any acceleration in sales growth representing upside potential for Insmed's financial model.
- Market Sentiment Shift: On Stocktwits, retail sentiment around INSM stock shifted from ‘bearish’ to ‘bullish’ in the past 24 hours, with message volume increasing from ‘low’ to ‘high’, indicating growing investor optimism regarding Insmed's future performance.
See More
US Stocks Surge as Oil Prices Plunge Over 10%
- Oil Price Plunge Fuels Market Surge: US stocks rallied sharply with the S&P 500 up 1.15%, the Dow Jones up 1.38%, and the Nasdaq 100 up 1.22%, as President Trump postponed strikes on Iranian energy infrastructure, alleviating geopolitical tensions and boosting investor sentiment.
- Bond Yields Decline: The 10-year Treasury yield fell from an 8-month high of 4.44% to 4.33%, providing support for equities as concerns over inflation pressures eased, which could influence future monetary policy decisions by the Federal Reserve.
- Mixed International Market Reactions: While US markets surged, European markets showed mixed results, with the Eurozone consumer confidence index dropping to a nearly 2.5-year low of -16.3, indicating economic uncertainty that may affect future investment strategies.
- Strong Performance from Tech Stocks: The so-called
See More
Airlines Surge Amid Easing Iran Tensions
- Airline Stocks Rally: Following President Trump's announcement that the U.S. would refrain from striking key energy infrastructure in Iran, Delta Air Lines, United Airlines, Southwest Airlines, and American Airlines saw their stock prices surge approximately 4%, indicating market optimism for a recovery in the airline sector.
- Travel-Related Stocks Rise: Optimism surrounding a resolution to the Iran conflict boosted online travel booking site Booking Holdings by nearly 2%, short-term rental platform Airbnb by almost 3%, and hotel chains Hyatt, Marriott, and Hilton by around 3%, reflecting expectations for a rebound in travel demand.
- Palantir Technologies Surge: Shares of Palantir Technologies jumped over 4% after reports that the Pentagon will designate its Maven AI system as the core military AI platform, effective by September 30, which is expected to provide stable, long-term funding for the company.
- Biotech Stocks Soar: Apogee Therapeutics' stock skyrocketed 20% after positive Phase 2 results for its zumilokibart treatment for moderate to severe atopic dermatitis, demonstrating the treatment's effectiveness and potentially enhancing the company's future market performance.
See More
Oil Price Plunge Boosts Stock Market Gains
- Market Surge: The S&P 500 rose by 2.10%, the Dow Jones by 2.30%, and the Nasdaq 100 by 2.19%, indicating a strong market response to the sharp drop in oil prices, which is expected to enhance corporate profitability.
- Oil Price Drop: Crude oil prices plummeted over 10% after President Trump postponed strikes on Iranian energy infrastructure, which will lower fuel costs for airlines and cruise lines, thereby boosting their profit margins.
- Bond Yields Decline: The 10-year Treasury yield fell from an 8-month high of 4.44% to 4.34%, reflecting reduced market concerns about inflationary pressures, which supports further stock market gains.
- International Tensions: Productive talks between Trump and Iran may lead to an end to the Middle East conflict, with the International Energy Agency reporting severe damage to over 40 energy sites across nine countries, potentially causing long-term disruptions to global supply chains.
See More
Stock Market Rises as Oil Prices Plunge
- Oil Price Plunge Impacts Market: Following President Trump's announcement to postpone strikes on Iranian energy infrastructure, crude oil prices fell over 7%, directly contributing to a 1.73% rise in the S&P 500 and a 1.97% increase in the Dow Jones, reflecting market optimism over easing geopolitical risks.
- Bond Yields Decline: The 10-year Treasury yield fell from an 8-month high of 4.44% to 4.27% on news of a potential end to the Iran war, indicating a reduction in investor concerns about inflationary pressures that could influence Federal Reserve policy decisions.
- Global Supply Chain Risks: The International Energy Agency reported that over 40 energy sites across nine Middle Eastern countries have been severely damaged due to the Iran war, potentially prolonging disruptions to global supply chains and affecting international market stability post-conflict.
- Strong Performance in Tech Stocks: Amidst the overall market rise, technology stocks like Tesla, Nvidia, and Amazon saw gains of over 2%, indicating increased investor confidence in the tech sector, which may lay the groundwork for future market growth.
See More
Insmed's Phase 3b Data Shows Significant Improvement for Arikayce
- Clinical Trial Results: Insmed's Arikayce demonstrated significant improvement in the Phase 3b trial, with a change in respiratory symptom score of 17.77 points in the active treatment group compared to 14.66 points in the placebo group, indicating substantial efficacy in patients with newly diagnosed Mycobacterium avium complex lung infections.
- Drug Combination Regimen: The active group received Arikayce daily along with 250 mg of azithromycin and 15 mg/kg of ethambutol, while the control group was treated with azithromycin, ethambutol, and a placebo, establishing a robust foundation for the drug's future applications.
- FDA Approval Process: Arikayce received accelerated approval in 2018 for refractory MAC lung infections, and this Phase 3b trial was conducted to fulfill post-marketing commitments to the FDA, further advancing the drug's market recognition.
- Future Plans: Insmed intends to file a New Drug Application (NDA) in the second half of the year to gain label expansion and obtain traditional approval for the existing refractory indication in the U.S., reflecting the company's confidence in Arikayce's future market potential.
See More
Insmed's Arikayce Trial Results Show Promise
- Buy Rating and Price Target: Truist has assigned a ‘Buy’ rating to Insmed shares with a price target of $205, indicating a potential upside of approximately 51% from Friday's closing price, reflecting strong market confidence in Insmed's future growth.
- Positive Trial Results: Insmed announced positive results from its trial of Arikayce for treating new occurrences of MAC lung infection, successfully meeting primary endpoints and demonstrating significant improvements in respiratory symptom scores and culture conversion rates, which may facilitate full FDA approval.
- Sales Growth Expectations: Truist analysts noted that while a better understanding of label expansion impacts is needed, they expect Arikayce's sales growth rate to remain stable, with any acceleration in sales growth representing upside potential for Insmed's financial model.
- Market Sentiment Shift: On Stocktwits, retail sentiment around INSM stock shifted from ‘bearish’ to ‘bullish’ in the past 24 hours, with message volume increasing from ‘low’ to ‘high’, indicating growing investor optimism regarding Insmed's future performance.
See More
US Stocks Surge as Oil Prices Plunge Over 10%
- Oil Price Plunge Fuels Market Surge: US stocks rallied sharply with the S&P 500 up 1.15%, the Dow Jones up 1.38%, and the Nasdaq 100 up 1.22%, as President Trump postponed strikes on Iranian energy infrastructure, alleviating geopolitical tensions and boosting investor sentiment.
- Bond Yields Decline: The 10-year Treasury yield fell from an 8-month high of 4.44% to 4.33%, providing support for equities as concerns over inflation pressures eased, which could influence future monetary policy decisions by the Federal Reserve.
- Mixed International Market Reactions: While US markets surged, European markets showed mixed results, with the Eurozone consumer confidence index dropping to a nearly 2.5-year low of -16.3, indicating economic uncertainty that may affect future investment strategies.
- Strong Performance from Tech Stocks: The so-called
See More
Airlines Surge Amid Easing Iran Tensions
- Airline Stocks Rally: Following President Trump's announcement that the U.S. would refrain from striking key energy infrastructure in Iran, Delta Air Lines, United Airlines, Southwest Airlines, and American Airlines saw their stock prices surge approximately 4%, indicating market optimism for a recovery in the airline sector.
- Travel-Related Stocks Rise: Optimism surrounding a resolution to the Iran conflict boosted online travel booking site Booking Holdings by nearly 2%, short-term rental platform Airbnb by almost 3%, and hotel chains Hyatt, Marriott, and Hilton by around 3%, reflecting expectations for a rebound in travel demand.
- Palantir Technologies Surge: Shares of Palantir Technologies jumped over 4% after reports that the Pentagon will designate its Maven AI system as the core military AI platform, effective by September 30, which is expected to provide stable, long-term funding for the company.
- Biotech Stocks Soar: Apogee Therapeutics' stock skyrocketed 20% after positive Phase 2 results for its zumilokibart treatment for moderate to severe atopic dermatitis, demonstrating the treatment's effectiveness and potentially enhancing the company's future market performance.
See More
Oil Price Plunge Boosts Stock Market Gains
- Market Surge: The S&P 500 rose by 2.10%, the Dow Jones by 2.30%, and the Nasdaq 100 by 2.19%, indicating a strong market response to the sharp drop in oil prices, which is expected to enhance corporate profitability.
- Oil Price Drop: Crude oil prices plummeted over 10% after President Trump postponed strikes on Iranian energy infrastructure, which will lower fuel costs for airlines and cruise lines, thereby boosting their profit margins.
- Bond Yields Decline: The 10-year Treasury yield fell from an 8-month high of 4.44% to 4.34%, reflecting reduced market concerns about inflationary pressures, which supports further stock market gains.
- International Tensions: Productive talks between Trump and Iran may lead to an end to the Middle East conflict, with the International Energy Agency reporting severe damage to over 40 energy sites across nine countries, potentially causing long-term disruptions to global supply chains.
See More
Stock Market Rises as Oil Prices Plunge
- Oil Price Plunge Impacts Market: Following President Trump's announcement to postpone strikes on Iranian energy infrastructure, crude oil prices fell over 7%, directly contributing to a 1.73% rise in the S&P 500 and a 1.97% increase in the Dow Jones, reflecting market optimism over easing geopolitical risks.
- Bond Yields Decline: The 10-year Treasury yield fell from an 8-month high of 4.44% to 4.27% on news of a potential end to the Iran war, indicating a reduction in investor concerns about inflationary pressures that could influence Federal Reserve policy decisions.
- Global Supply Chain Risks: The International Energy Agency reported that over 40 energy sites across nine Middle Eastern countries have been severely damaged due to the Iran war, potentially prolonging disruptions to global supply chains and affecting international market stability post-conflict.
- Strong Performance in Tech Stocks: Amidst the overall market rise, technology stocks like Tesla, Nvidia, and Amazon saw gains of over 2%, indicating increased investor confidence in the tech sector, which may lay the groundwork for future market growth.
See More
Insmed's Phase 3b Data Shows Significant Improvement for Arikayce
- Clinical Trial Results: Insmed's Arikayce demonstrated significant improvement in the Phase 3b trial, with a change in respiratory symptom score of 17.77 points in the active treatment group compared to 14.66 points in the placebo group, indicating substantial efficacy in patients with newly diagnosed Mycobacterium avium complex lung infections.
- Drug Combination Regimen: The active group received Arikayce daily along with 250 mg of azithromycin and 15 mg/kg of ethambutol, while the control group was treated with azithromycin, ethambutol, and a placebo, establishing a robust foundation for the drug's future applications.
- FDA Approval Process: Arikayce received accelerated approval in 2018 for refractory MAC lung infections, and this Phase 3b trial was conducted to fulfill post-marketing commitments to the FDA, further advancing the drug's market recognition.
- Future Plans: Insmed intends to file a New Drug Application (NDA) in the second half of the year to gain label expansion and obtain traditional approval for the existing refractory indication in the U.S., reflecting the company's confidence in Arikayce's future market potential.
See More
